Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
10 mai 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20,...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
06 mai 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. ...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
22 avr. 2021 16h01 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
21 avr. 2021 08h00 HE
|
Vir Biotechnology, Inc.
DURHAM, N.C. and BEIJING and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Brii Biosciences (“Brii Bio”), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc....
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 16h01 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
17 févr. 2021 07h04 HE
|
Vir Biotechnology, Inc.
– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza – – Functional genomics...
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
11 févr. 2021 16h01 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
10 déc. 2020 08h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three...
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
21 oct. 2020 08h00 HE
|
Vir Biotechnology, Inc.
– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1 demonstrates potential...
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
31 août 2020 08h00 HE
|
Vir Biotechnology, Inc.
Phase 2/3 COMET-ICE study will investigate the safety and efficacy of antibody treatment in preventing hospitalization due to COVID-19 Potential for initial study results to be available before the...